Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

About this Publication
Title
Overall and non- lung cancer incidence and mortality in the National Lung Screening Trial: Opportunities for multi-cancer early detection
Digital Object Identifier
Publication
Cancer Med. 2024 Jun 22; Volume 13 (Issue 12)
Authors
Alpa V. Patel 1 | Ellen T. Chang 2 | Allan Hackshaw 3 | Sam M. Janes 4 |Diana S. M. Buist 2 | Earl Hubbell 2 | Christina A. Clarke 2 | Graham A. Colditz 5
Affiliations
  • 1 American Cancer Society, Atlanta,Georgia, USA
  • 2 GRAIL, LLC, Menlo Park, California,USA
  • 3 Lung for Living, UCL Respiratory,University College London, London,UK
  • 4 Department of Respiratory Medicine,University College London, London,UK
  • 5 Washington University School ofMedicine, St. Louis, Missouri, USA
Abstract

Abstract
Background: Currently recommended cancer screening programs address only part of the overall population cancer burden. Even populations deemed high- risk for certain individual cancers experience a considerable potential burden of other cancers. However, few published cancer screening trials report the incidence of untargeted cancers.

Methods: The National Lung Screening Trial (NLST), initiated in 2002–2004,was a randomized controlled trial of lung cancer screening in adults with ≥30pack-years of smoking. Active follow-up for incident invasive cancers continued through 2009.

Results: Among 53,229 NLST subjects (median follow-up 6.5 years after randomization), the incidence of lung cancer was 615 per 100,000 person-years (32%of 6142 overall first primary incident invasive cancers), and that of non-lung cancer was 1327 per 100,000 (68%). Non-lung cancer incidence exceeded that for lung cancer in all 5-year age categories and all quintiles of smoking pack-years. Besides lung cancer, the most common cancers were prostate, breast, colon/rec-tum, bladder, and head/neck; 23% were smoking-related cancers, and 54% were cancer types lacking recommended population-based screening modalities (32%excluding prostate). Non-lung cancer comprised 48% of 1793 cancer deaths.

Conclusions: In the NLST, only 32% of first primary cancer incidence after study entry was lung, compared with 68% non-lung. Even in a population at high risk for lung cancer, a single-cancer screening test misses most cancers. Thus, in com-bination with existing single-cancer screening modalities, multi-cancer screening tests—which address many of the incident non-lung cancers in this trial—have potential to address a currently inaccessible portion of cancer morbidity and mortality.

Related CDAS Studies
Related CDAS Projects